ICP
RUBY

Interchange Capital Partners’s Rubius Therapeutics, Inc RUBY Stock Holding History

Interchange Capital Partners’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-668
Closed -$5K – 1189
2020
Q4 		$5K Buy
+668
New +$3.97K ﹤0.01% 953

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AFM
Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Interchange Capital Partners's RUBY Position: Q1 2021 in Review

Interchange Capital Partners sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2021, closing a stake of 668 shares — an estimated $5K sold.

Interchange Capital Partners first reported a position in RUBY in Q4 2020 and held it in 1 quarter. The position peaked at $5K in Q4 2020. 105 funds tracked by Wall St. Rank hold RUBY as of Q1 2021.

  • Interchange Capital Partners reported no remaining Rubius Therapeutics, Inc position as of Q1 2021 after selling out during the quarter.
  • Interchange Capital Partners sold 668 Rubius Therapeutics, Inc shares in Q1 2021, an estimated $5K.
  • Interchange Capital Partners first reported a position in Rubius Therapeutics, Inc in Q4 2020 and held it in 1 quarter.
  • Interchange Capital Partners's Rubius Therapeutics, Inc position peaked at $5K in Q4 2020.
  • 105 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2021.

Based on Interchange Capital Partners's 13F filing for Q1 2021, filed 5 May 2021.